Neumo­ra, Rayze­Bio ride on­to Nas­daq in IPO dou­ble­head­er, breath­ing life in­to fall list­ings

Two Phase III biotechs will join the Nas­daq Fri­day morn­ing, with ra­dio­phar­ma start­up Rayze­Bio and brain dis­ease drug de­vel­op­er Neumo­ra pric­ing their IPOs at $311 mil­lion and $250 mil­lion, re­spec­tive­ly.

Rayze­Bio and Neumo­ra wooed in­vestors dur­ing a rel­a­tive­ly icy IPO mar­ket, which is be­gin­ning to thaw as oth­er biotech star­tups are lin­ing up to go pub­lic. The Fri­day dou­ble­head­er — the sec­ond of its kind in re­cent months af­ter Apogee and Sagimet en­tered Wall Street on the same day in Ju­ly — could be a boon to oth­er pri­vate biotechs ea­ger to go pub­lic this fall, which is an­tic­i­pat­ed to be about 10 com­pa­nies, per in­dus­try in­sid­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER